Clinical Trial Update: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating mirvetuximab soravtansine as monotherapy in platinum-sensitive epithelial ovarian cancer, peritoneal cancer, and fallopian tube cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Mirvetuximab soravtansine (mirvetuximab soravtansine)

Snippet

Sponsor: AbbVie | Conditions: Ovarian Cancer, Peritoneal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2026-01-09